Stock Events

Stock Events

Allakos 

0
646
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

83.46%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
86.53MRevenue
72.21MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 37Z.MU. It's not an investment recommendation.
Legal & General Group
160
LGEN.LSE
Supermarket Income REIT
122
SUPR.LSE
Greencoat UK Wind
121
UKW.LSE
Primary Health Prop.
120
PHP.LSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Primary Health Prop.
PHP.LSE
Mkt Cap2.43B
Medical Properties Trust
MPW
Mkt Cap3.02B
Medical Properties Trust, an American company investing in hospital buildings, competes in the healthcare real estate market globally.
Healthcare Realty Trust
HR
Mkt Cap7.26B
Healthcare Realty Trust is involved in owning, managing, and developing healthcare properties, directly competing in the healthcare real estate sector.
Pebblebrook Hotel Trust
PEB
Mkt Cap2.06B
Pebblebrook Hotel Trust, though more focused on hotels, has investments in properties that can be repurposed for healthcare, offering indirect competition.
Ventas
VTR
Mkt Cap44.08B
Ventas, Inc. invests in a diverse range of healthcare properties, including hospitals and senior living facilities, making it a competitor.
Welltower
WELL
Mkt Cap163.48B
Welltower Inc. focuses on health care infrastructure, including senior housing and outpatient medical properties, competing for similar investment.
Omega Healthcare Investors
OHI
Mkt Cap15.06B
Omega Healthcare Investors, Inc. focuses on long-term healthcare facilities, directly competing in the healthcare REIT sector.
National Health Investors
NHI
Mkt Cap3.65B
National Health Investors, Inc. invests in healthcare properties, including senior living and medical office buildings, making it a competitor.

About

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.
Show more...
CEO
Employees
167
Country
United Kingdom
ISIN
US01671P1003

Listings

MU
DE
37Z.MU
F
DE
37Z.F
LSE
GB
THRL.LSE

0 Comments

Share your thoughts

FAQ

What is Allakos stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Allakos stocks are traded under the ticker 37Z.MU.
What is Allakos revenue for the last year?▼
Allakos revenue for the last year amounts to 86.53M EUR.
What is Allakos net income for the last year?▼
37Z.MU net income for the last year is 72.21M EUR.
How many employees does Allakos have?▼
As of July 18, 2026, the company has 167 employees.
In which sector is Allakos located?▼
Allakos operates in the Health & Wellness sector.
When did Allakos complete a stock split?▼
Allakos has not had any recent stock splits.